drugset / Trial / NCT02065609
89ZrTrastuzumab Breast Imaging With Positron Emission Tomography
Phase 0
Completed
52 enrolled
Washington University School of Medicine
National Cancer Institute (NCI) · collab
Non-randomizedSingle-groupOpen-labelDiagnostic
Summary
The main purpose of this study is to see if Positron Emission Tomography (PET-Imaging) with 89Zr labeled trastuzumab can detect trastuzumab (HER2) positive breast cancer.
Timeline
- Start
- 2014-02
- Primary completion
- 2017-12-31
- Completion
- 2018-02-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 89Zr-trastuzumab | Diagnostic / imaging agent | — | — |